Best FDA-Approved GLP-1 on Capital Rx Formulary (2026): What’s Covered, What Needs Prior Authorization, and How to Check Your Plan

Published: June 16, 2026 · Last reviewed: June 16, 2026

By The RX Index Editorial Team

Quick answer: the best FDA-approved GLP-1 on Capital Rx formulary by situation

This maps your reason for wanting a GLP-1 to the drug that makes the most sense to ask about first, based on the Capital Rx Liberty Formulary and each drug’s FDA-approved use.

The truly best option is the one your plan covers at the lowest tier and your doctor agrees is right for your health. We can tell you what Capital Rx lists. Only your prescriber can tell you what’s right for your body.

What we actually verified (June 16, 2026)

We don’t ask you to take our word for it. Here’s exactly what we checked — and what we couldn’t.

Prices and coverage change. We re-verify this page on the schedule in the Sources table at the end.

Which FDA-approved GLP-1s are actually on the Capital Rx formulary?

On the Capital Rx Liberty Formulary, the covered FDA-approved GLP-1s are Ozempic, Mounjaro, Rybelsus, and Trulicity for type 2 diabetes (all Tier 2), and Wegovy (shot and pill), Zepbound, and generic liraglutide for weight management. Every standalone GLP-1 requires prior authorization.

Capital Rx GLP-1 coverage — type 2 diabetes lane

Also listed, but not standalone GLP-1s: Soliqua and Xultophy are insulin-incretin combination products (insulin paired with a GLP-1). On the Liberty Formulary they sit at Tier 2 with quantity limits only — no prior authorization on those rows. They aren’t a first ask for GLP-1 therapy; they’re for specific insulin-plus-GLP-1 situations your doctor would decide on.

Capital Rx GLP-1 coverage — weight-management lane

Three things worth knowing right away

1. No standalone GLP-1 skips prior authorization on Capital Rx. Not one. Plan for it.
2. Bydureon BCise is the only one at Tier 3. That usually means a higher cost — so it’s rarely the smart first ask.
3. Foundayo, the brand-new oral pill, wasn’t found on the formulary we reviewed — more on that below.

Why “on the list” doesn’t always mean “covered for you”

This is the single most expensive misunderstanding in GLP-1 coverage. Capital Rx is a pharmacy benefit manager (PBM) — the company that runs the prescription side of your plan. It publishes the Liberty Formulary as a standard template. But your employer (the “plan sponsor”) gets to customize it. They can change tiers, add rules, and — most importantly — leave out whole drug categories, like weight-loss drugs. So a drug can be printed right there on the formulary and still not be covered for you.

Capital Rx is explicit about this: its formulary says a listed drug “may not be covered if your plan does not include coverage of certain categories.” The only way to know for sure is to check your own plan.

Does Capital Rx cover GLP-1s for weight loss, or only diabetes?

The Capital Rx Liberty Formulary lists weight-loss GLP-1s (Wegovy, Zepbound, generic liraglutide) and diabetes GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity). But coverage for the weight-loss ones depends on whether your employer chose to include the weight-loss drug category — and many don’t. Here’s the plain-English version:

• Wegovy and Zepbound are the FDA-approved weight-loss brands. Coverage for them is the one most likely to be excluded.
• Ozempic, Mounjaro, Rybelsus, and Trulicity are diabetes brands. If you have type 2 diabetes, you’re usually in a stronger spot.
• Insurance generally follows the FDA-approved use and your plan’s rules — not what a friend got covered, and not off-label hopes.

Zepbound vs. Wegovy on Capital Rx: which should you ask about first?

For weight loss, Zepbound is the strongest first ask if you and your doctor want tirzepatide and your plan covers weight-loss drugs — it’s also the only option with a sleep-apnea use. Wegovy is the better first ask if you want semaglutide, prefer a once-daily pill, or your doctor is focused on heart-risk reduction. Both are Tier 2 on Capital Rx and both need prior auth.

What about Ozempic or Mounjaro through Capital Rx?

Ozempic and Mounjaro are on the Capital Rx Liberty Formulary at Tier 2 with prior authorization — but in the diabetes section, not the weight-loss section. That matters.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes blood-sugar control. Its label also includes lowering the risk of major heart events in adults with type 2 diabetes and known heart disease, and lowering kidney-related risks in adults with type 2 diabetes and chronic kidney disease. It is not FDA-approved for weight loss. On Capital Rx it’s Tier 2 with prior auth and a quantity limit of 3 mL per 28 days.

Mounjaro (tirzepatide) is FDA-approved as an add-on to diet and exercise to improve blood-sugar control in adults and children 10 years and older with type 2 diabetes (the pediatric use was added in late 2025). On Capital Rx it’s Tier 2 with prior auth (the 2.5 mg starter dose carries a custom quantity limit). If your goal is weight loss rather than diabetes, Zepbound is the tirzepatide brand to ask about, not Mounjaro.

The takeaway: if you have type 2 diabetes, the diabetes-lane GLP-1s are your most reliable covered path. If your goal is purely weight loss, asking for a diabetes brand off-label usually leads to a denial — the weight-loss brands are the cleaner route.

Is Foundayo (the new GLP-1 pill) on the Capital Rx formulary?

Foundayo is FDA-approved, but it was not found in the public Capital Rx Liberty Formulary we reviewed. That doesn’t prove your specific plan will never cover it — it means you shouldn’t assume it’s covered until you check your own portal.

Foundayo (orforglipron) is Eli Lilly’s once-daily oral GLP-1 pill. The FDA approved it on April 1, 2026 for chronic weight management in adults with obesity, or overweight plus a weight-related condition. Its big selling point: a pill you can take any time of day, with no food or water rules.

If you want an oral GLP-1 that’s on the formulary today, Rybelsus (for diabetes) or the oral Wegovy tablet (for weight) are the covered choices. If your plan doesn’t cover Foundayo, cash-pay routes start around $149/month for new patients on the lowest doses — but confirm before assuming.

PA, QL, and QLC: what these codes mean, and whether they’ll block you

PA (prior authorization) means the plan must approve the drug before it’s covered; your doctor submits the paperwork. QL (quantity limit) caps how much you can get per fill or per month. QLC is a custom version of that cap, common on low starter doses. Every standalone GLP-1 on Capital Rx has a PA, and most have a QL or QLC — knowing what they mean keeps you from getting blindsided at the pharmacy.

The Capital Rx GLP-1 Coverage Decoder

Staring at “Tier 2 · PA · QLC 2/180” and have no idea what it means for you? Use this quick decode while you have your portal open:

We’re building this as an interactive tool so you can type in your own row and get a personalized checklist. Until then, the decode list above does the job.

What you’ll actually pay with Capital Rx

If your Capital Rx plan covers the GLP-1, you pay your plan’s tier cost-share — not the sticker price. In Ro’s own coverage data, half of covered patients paid $50 a month or less in copay. If your plan doesn’t cover it, brand-name cash prices now start around $149/month for the lowest-dose pills — a fraction of the $968 to $1,349 retail list price.

Which provider should a Capital Rx member use for FDA-approved GLP-1s?

For this specific need — FDA-approved drugs plus insurance navigation — Ro is the best fit, because it pairs a free coverage checker with an insurance concierge that files your prior authorization (on commercial plans). Sesame Care is the strong second choice if you want to pick your own clinician or you’re a Costco member.

Best first path: Ro

Best for: Capital Rx members with a commercial or employer plan who want an FDA-approved GLP-1 and real help with coverage or prior authorization.

• A free GLP-1 Insurance Coverage Checker that contacts your insurer and returns a written report — your coverage, whether prior auth is needed, and your estimated copay. No prescription required.
• A dedicated insurance concierge that verifies your benefits and submits the prior-authorization paperwork for you, then follows up. The insurance route takes about 2–3 weeks.
• Through insurance, Ro’s concierge works to get coverage for brand-name GLP-1s — typically the Wegovy pen, Zepbound, and Ozempic.
• If your plan won’t cover it (or you’d rather pay cash), Ro offers FDA-approved cash-pay options — Wegovy pill, Foundayo pill, Zepbound KwikPen, Wegovy pen, and Ozempic — at prices matching LillyDirect, NovoCare, and TrumpRx.
• Pricing: $39 for the first month, then as low as $74/month with an annual plan paid upfront, or $149/month month-to-month. Medication is billed separately; HSA/FSA receipts can be submitted for reimbursement. Verify current pricing.

And here’s the part most affiliate pages won’t say out loud: if your Capital Rx plan already covers your GLP-1, you don’t need a telehealth membership at all. Your own doctor plus your pharmacy benefit is the cheapest path, full stop. A concierge like Ro earns its keep when your plan excludes the drug (and you want a transparent cash price), or you’d rather not chase the prior-auth paperwork yourself. If neither is you, take this page to your doctor and skip the fee.

Want the deeper breakdown first? Read our full Ro Body review.

Best second path: Sesame Care

Best for: people who want to choose their own clinician, or who are Costco members wanting Costco/Novo pricing on Wegovy or Ozempic.

• Sesame lets you browse provider profiles and pick your own clinician — most platforms just assign one.
• Costco members get Wegovy or Ozempic shots around $349/month (new patients about $199/month for the first two months) and the Wegovy pill from about $149/month through the Costco Member Prescription Program with Sesame.
• One of the broadest branded menus: Wegovy (shot and pill), Zepbound, Ozempic, Mounjaro, Foundayo, Rybelsus, and more.
• Subscription around $99 every 28 days (lower with annual plans or the Costco-linked plan); medication is billed separately. Verify current pricing.

More detail: read our Sesame Care review.

Why we don’t rank compounded providers on this page

You searched for an FDA-approved GLP-1 on a formulary. Compounded GLP-1s are a different thing entirely. Compounded means a pharmacy mixes a custom version of the drug. The FDA warns that compounded GLP-1s do not go through FDA review for safety, effectiveness, or quality. They are not the same as the FDA-approved brands on this page, and they’re never what a formulary covers. Mixing them into a “best FDA-approved on Capital Rx” answer would be misleading — so we keep them out of this one.

Provider-stated vs. verified

Prices and medication availability change; confirm on each provider’s site before you act.

What if Capital Rx denies your GLP-1?

A denial isn’t always the end. First find out why — missing paperwork, the wrong diagnosis lane, a plan exclusion, step therapy, a quantity-limit issue, or a brand-new drug not yet reviewed. Then ask about an appeal, a formulary exception, or a covered alternative. Many denials are fixable.

A formulary exception is a request asking the plan to cover a drug it normally wouldn’t, backed by your doctor’s clinical notes. Capital Rx says a drug-exception request with clinical documentation can be submitted when your prescriber decides you need a drug that isn’t covered on the Liberty Formulary. It’s worth trying when the medical case is strong.

What if you have Capital Rx through Medicare?

If your Capital Rx pharmacy benefit is a Medicare Part D plan, GLP-1s are covered for FDA-approved medical conditions like type 2 diabetes — but Medicare still excludes coverage for weight loss alone. Starting July 1, 2026, the new federal Medicare GLP-1 Bridge lets eligible members get Foundayo, Wegovy, or the Zepbound KwikPen for weight at a flat $50/month copay — if they qualify. In 2026, Part D also caps your out-of-pocket costs for covered Part D drugs at $2,100 for the year.

The Bridge begins July 1, 2026. Eligible weight-loss drugs are Foundayo, all forms of Wegovy, and the Zepbound KwikPen when used to reduce excess body weight, at a flat $50/month copay; CMS covers the rest. Your doctor still has to submit a prior auth.

Important routing: Ro’s concierge does not handle government insurance. If you’re on Medicare, work through your own prescriber and the Bridge — don’t count on a telehealth concierge to coordinate it.

The honest downsides before you start

The biggest downside is that being on the Capital Rx formulary doesn’t guarantee your plan will pay. The others: prior auth can delay or block you, plans can exclude weight-loss drugs, starter-dose limits can surprise you, and a brand-new drug like Foundayo may not be covered yet.

• A listed drug isn’t a personal guarantee. Your employer can exclude categories. Verify your plan.
• Prior auth is required for every standalone GLP-1 here. Expect a short wait and some paperwork.
• Starter-dose quantity limits (QLC) can differ from your maintenance months. Normal, but plan for it.
• Even covered, the cost may not be tiny. Your deductible and tier decide your real out-of-pocket.
• FDA-approved doesn’t mean right for everyone. These drugs carry warnings and side effects, and shouldn’t be combined with other GLP-1s unless your doctor and the label support it. Your clinician decides if treatment is safe for you.

What to ask your doctor to put in the prior authorization

A strong prior auth matches the drug to its FDA-approved use and your plan’s rules. Your doctor controls the clinical submission, but you can speed it up by bringing your coverage details, diagnosis history, and the formulary screenshot.

How we picked the best FDA-approved GLP-1s on Capital Rx

We ranked options by five things: their signal on the Capital Rx formulary, how well they match an FDA-approved use, how much prior-auth and quantity friction they carry, how confidently you can verify coverage, and what your fallback is if your plan says no. We deliberately did not rank compounded drugs — this page is about FDA-approved GLP-1s on a formulary.

That’s why Zepbound and Wegovy lead for weight loss (FDA-approved weight brands in the formulary’s anti-obesity section), Ozempic and Mounjaro lead for diabetes (diabetes-labeled, in the diabetes section), and Foundayo gets a “verify first” flag (FDA-approved, but not found on the formulary we reviewed).

See also: Best GLP-1 Online Programs in 2026 | How Find My Path Works | Our Decision Methodology

Frequently asked questions

Sources and last-verified dates

We re-check the formulary quarterly and provider pricing monthly, and update the date above. Pricing and medication availability can change between updates — confirm current figures before acting.